Cell cycle regulation and control of angioplasty restenosis

Advanced Drug Delivery Reviews

Volumn 24, Issue 1, 1997, Pages 45-51

  Welt, Frederick G P ^a   Edelman, Elazer R ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

angioplasty; cell cycle; restenosis

Indexed keywords

BLOOD VESSELS; CELLS; CYTOLOGY; DISEASES; DRUG THERAPY; ENZYMES; MUSCLE;

ANGIOPLASTY; CELL CYCLE; PROLIFERATION; RESTENOSIS;

CARDIOLOGY;

ANTISENSE OLIGODEOXYNUCLEOTIDE; ELONGATION FACTOR 2; ETHYLENE VINYL ACETATE COPOLYMER; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; NUCLEAR PROTEIN; PLATELET DERIVED GROWTH FACTOR; POLYMER; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; TYRPHOSTIN;

ANGIOPLASTY; ARTERY OCCLUSION; ATHEROSCLEROSIS; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; DRUG ADMINISTRATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; LEUKOCYTE ADHERENCE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE; VASCULAR DISEASE;

EID: 0031568932     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00481-4     Document Type: Review

References (25)

1. [1] Rensing, B.J., Hermans, W.R., Beatt, K.J., Laarman, G.J. Suryapranata, H., van den Brand, M., De Feyer, P.Y. and Serruys, P.W. (1990) Quantitative angiographic assessment of elastic recoil after PTCA. Am. J. Cardiol., 66, 1039-1044.
2. [2] Libby, P., Schwartz, D., Brogi, E., Tanaka, H. and Clinton, S.K. (1992) A cascade model for restenosis: a special case of atherosclerosis progression. Circulation, 86 Suppl. III, III-47-52.
3. [3] Ross, R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-808.
4. [4] Lau, K. and Sigwart, U. (1995) Restenosis - an accelerated arteriopathy: pathophysiology, preventive strategies and research horizons. In: Edelman, E.R. (Ed), Molecular Interventions and Local Drug Delivery, pp. 1-28. W.B. Saunders, London.
5. [5] Nobuyushi, M., Kimura, T., Ohishi, H., Horiuchi, H., Nosaka, H., Hamasaka, N., Yokoi, H. and Kim, K. (1991) Resenosis after PTCA: pathological observations in 20 patients. J. Am. Coll. Cardiol., 17, 433-439.
6. [6] Garratt, K.N., Edwards, W.D., Kaufmann, U.P., Vlietstra, R.E. and Holmes, D.R. Jr. (1991) Differential histopathology of primary atherosclerotic and estenotic lesions in coronary arteries and saphenous vein bypass grafts: analysis of tissue obtained from 73 patients by directional atherectomy. J. Am. Coll. Cardiol., 17, 442-448.
7. [7] Sigwart, U., Mirkovitch, V., Joffre, F. and Kappenberger, L. (1987) Intravascular stents to prevent reocclusion and restenosis after transluminal angioplasty. N. Engl. J. Med., 316, 701-706.
8. [8] Carroza, J.P., Kuntz, R.E., Levine, M.J., Pomerantz, R.M., Fishman, R.F., Mansour, M., Gibson, C.M., Senerchia, C.C., Diver, D.J., Safian, R.D. and Baim, D.S. (1992) Angiographic and clinical outcome of intracoronary stenting: immediate and long term results from a large single-center experience. J. Am. Coll. Cardiol. 20, 328-337.
9. [9] Serruys, P.W., Strauss, B.H., Beatt, K.J., Bertrand, M.E., Puel, J., Rickards, A.F., Meier, B., Goy, J.J., Vogt, P., Kappenberger, L. and Sigwart, U. (1991) Angiographic follow-up of a self-expanding coronary-artery stent. N. Engl. J. Med. 324, 13-17.
10. [10] Kuntz, R.E., Gibson, C.M., Noboyushi, M. and Baim, D.S. (1993) Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J. Am. Coll. Cardiol. 21, 15-25.
11. [11] Kuntz, R.E., Safian, R.D., Carrozza, J.P., Fishman, R.F., Mansour, M. and Baim, D.S. (1992) The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation, 86, 1827-1835.
12. [12] Goodman, S.R. (1994) Medical Cell Biology. J.B. Lippincott, Philadelphia, PA.
13. [13] Yarden, Y. and Ullrich, A. (1988) Growth factor receptor tyrosine kinases. Annu. Rev. Biochem., 57, 443-478.
14. [14] Levitzki, A. and Gazit, A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science, 267, 1782-1788.
15. [15] Bilder, G.E., Krawiec, J.A., McVety, K., Gazit, A., Gilon, C., Lyall, R., Zilberstein, A., Levitzki, A., Perrone, M.H. and Schreiber, A.B. (1991) Tyrophostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol., 260, C721-730.
16. [16] Murray, A. and Hunt, T. (1993) The Cell Cycle: An Introduction. Oxford University Press, Oxford.
17. [17] Hollingsworth, R.E. Jr., Hensey, C.E. and Lee, W. (1993) Retinoblastoma protein and the cell cycle. Curr. Opin. Genet. Dev. 3, 55-62.
18. [18] Chang, M.W., Barr, E., Seltzer, J., Jiang, Y., Nabel, G.J., Nabel, E.G., Parmacek, M.S. and Leiden, J.M. (1995) Cytostatic gene therapy for vascular proliferative disorders with a constituitively active form of the retinoblastoma gene product. Science, 267, 518-522.
19. [19] Morishita, R., Gibbons, G.H., Horiuchi, M., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Oghiara, T. and Dzau, V.J. (1995) A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA, 92, 5855-5859.
20. [20] Morishita, R., Gibbons, G.H., Horiuchi, M., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Oghiara, T. and Dzau, V.J. (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA. 90, 8474-8478.
21. [21] Morishita, R., Gibbons, G.H., Kaneda, Y., Ogihara, T. and Dzau, V.J. (1994) Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and cdc2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 149, 13-19.
22. [22] Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., von der Leyen, H., Zhang, L., Kaneda, Y., Oghiara, T. and Dzau, V.J. (1994) Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest., 93, 1458-1464.
23. [23] Edelman, E.R., Simons, M., Sirois, M.G. and Rosenberg, R.D. (1995) C-myc in vasculoproliferative disease. Circ. Res., 76, 176-182.
24. [24] Simons, M. and Rosenberg, R.D. (1992) Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res., 70, 835-843.
25. [25] Simons, M., Edelman, E.R., DeKeyser, J.L., Langer, R. and Rosenberg, R.D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature, 359, 67-70.